Topics
News
CME/CE
Editorial Advisory Board
Partners
Subscribe
- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Quiz
Article
Understanding Biologic Options in Atopic Dermatitis Management
Author(s):
Test your knowledge on approved biologics in the management of moderate to severe atopic dermatitis and considerations for an 18-year-old man's case.
The vast treatment landscape to treat atopic dermatitis (AD) requires transparency and shared decision making with patients. Peter Lio, MD, and April Armstrong, MD, MPH, led a session at the 2023 Fall Clinical Dermatology Conference focusing on the biologic options available.1
Test your knowledge of the condition, the biologic treatment landscape, and considerations in the case of an 18-year-old man.
What is the prevalence of AD in children and adults?
References
- Armstrong A, Lio P. Closing the Health Care Gaps in the Management of Moderate to Severe Atopic Dermatitis With Biologics. Presented at: 2023 Fall Clinical Dermatology Conference; October 19-22, 2023, Las Vegas, NV.
- Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016;387(10023):1109-1122. doi:10.1016/S0140-6736(15)00149-X
- Irvine AD, Mina-Osorio P. Disease trajectories in childhood atopic dermatitis: an update and practitioner's guide. Br J Dermatol. 2019;181(5):895-906. doi:10.1111/bjd.17766
Related Content
